Adnexus Therapeutics

Compound Therapeutics and Abbott Laboratories Enter into Technology License Agreement for Drug Discovery

Compound Therapeutics and Abbott Laboratories Enter into Technology License Agreement for Drug Discovery

September 29, 2004

WALTHAM, Mass., Sept. 29 /PRNewswire/ -- Compound Therapeutics, a Massachusetts-based biotechnology company, announced today that they have entered into a license agreement with Abbott Laboratories granting Abbott non- exclusive rights to use Compound Therapeutics' PROfusion(TM) technology and certain antibody libraries. PROfusion is an in vitro display technology for the selection and rapid optimization of high-affinity antibodies and other binding proteins.

Black Duck Software, Inc.

Black Duck Names Noted Open Source Attorney Lawrence Rosen as Senior Advisor

Black Duck Names Noted Open Source Attorney Lawrence Rosen as Senior Advisor

October 4, 2004

Waltham, Mass., October 4, 2004 -- Black Duck Software, the leading provider of software compliance management solutions for governing software assets, today announced that Lawrence Rosen has joined the company as a senior advisor. Rosen, a noted attorney and computer specialist, is the author of Open Source Licensing: Software Freedom and Intellectual Property Law, which was published earlier this year.

Selventa

Genstruct Enters Into a Multi-Year Collaboration

Genstruct Enters Into a Multi-Year Collaboration

November 8, 2004

CAMBRIDGE, Mass., Nov. 8 /PRNewswire/ -- Genstruct Inc., a knowledge-driven discovery company, announced today that it has signed an agreement with Pfizer to collaborate on a variety of research projects to help better understand complex diseases. This deal is part of a continuing, multiyear relationship Genstruct has developed with Pfizer. Terms of the partnership are not being disclosed.

e-Dialog, Inc.

e-Dialog Strengthens Leadership Team and Increases Client Resources to Meet Growing Demand for Precision E-Mail Marketing

e-Dialog Strengthens Leadership Team and Increases Client Resources to Meet Growing Demand for Precision E-Mail Marketing

November 16, 2004

Company Appoints Three New Vice Presidents to Analytics, Sales, Marketing and Professional Services; Significantly Boosts Client Service Teams

BG Medicine, Inc.

FDA and Industry to Collaborate on Better Ways to Predict Liver Toxicity in Human Drug Trials

FDA and Industry to Collaborate on Better Ways to Predict Liver Toxicity in Human Drug Trials

November 2, 2005

Part of FDA’s Critical Path Initiative to Modernizing Drug Development

The U.S. Food and Drug Administration and BG Medicine, a Massachusetts-based biotechnology research company, have agreed to collaborate on a project designed to overcome one of the obstacles to efficient development of safe drugs.

TripAdvisor LLC

Flagship Portfolio Companies Highlighted in Boston Globe Articles

Flagship Portfolio Companies Highlighted in Boston Globe Articles

January 18, 2005

Three of Flagship's portfolio companies that specialize in Internet search technology were highlighted prominently in two articles in The Boston Globe's Sunday Business section on Monday, January 17, 2005. All three represent investments made by Flagship when other venture capital firms were retrenching and cautious about supporting search technologies. We continued to believe that there was money to be made in this area, and today all three companies (EasyAsk, Eliyon Technologies, and TripAdvisor) are in revenue phases, near or well beyond break-even.

Adnexus Therapeutics

Compound Therapeutics, Inc. Raises $15.5 Million to Advance Product Pipeline Into Clinic

Compound Therapeutics, Inc. Raises $15.5 Million to Advance Product Pipeline Into Clinic

January 18, 2005

WALTHAM, Mass., Jan. 18 /PRNewswire/ -- Compound Therapeutics, Inc., a privately held biotechnology company, today announced that it has raised an additional $15.5 million in an expansion of its Series A financing. These funds will be used to advance Compound's lead oncology product candidate into the clinic and to build the company's pipeline by moving additional programs into preclinical development. Compound is developing the next generation of biotherapeutics with its AdNectin and AdZyme technologies.

Flagship Ventures Has Moved Effective January 31, 2005

Flagship Ventures Has Moved Effective January 31, 2005

January 31, 2005


is pleased to announce

our new address effective January 31, 2005:

e-Dialog, Inc.

e-Dialog Posts 49 Percent Revenue Growth in 2004

e-Dialog Posts 49 Percent Revenue Growth in 2004

February 1, 2005

Emphasis on Strategy and Flexible Service Offerings Fuels Momentum in the Marketplace

BG Medicine, Inc.

Beyond Genomics Becomes BG Medicine, Appoints Pieter Muntendam, MD President; Moves Underscore Sharpened Focus On Drug Development Applications

Beyond Genomics Becomes BG Medicine, Appoints Pieter Muntendam, MD President; Moves Underscore Sharpened Focus On Drug Development Applications

February 3, 2005

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 3, 2005--Beyond Genomics, Inc. today announced its name change to BG Medicine Inc. The company also announced the appointment of Pieter Muntendam, MD as its new President to lead the company's business operations and strategy. BG Medicine's new name and new leadership reflect the decision to focus on high-value drug development applications of its proprietary Systems Pharmacology platform that is based on the scientific advances in the nascent Systems Biology field.